SOAT1 expression associates with prognosis, immune environment and biochemical indicators in glioma Authors: Weihua Hu, Wulong Liang, Xuyang Guo, Fangyuan Wang, Zhou Jing, Bingqi Lu, Hao Li, Shaolong Zhou, Ao Huo, Chenglin Zhao, Qingyi Wang, Shipeng Liang, Xudong Fu, Xinjun Wang Published: 2026 ABSTRACT AbstractPurposeThis study aims to investigate the association between sterol O-acyltransferase 1 (SOAT1) expression and patient prognosis, immune environment, and biochemical indicators in glioma.MethodsWe analyzed SOAT1 expression, immune cell infiltration, and patient prognosis using glioma cohorts from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. A retrospective cohort of 195 glioma patients who underwent surgical resection at our institution between January 2016 and December 2020 was also included. Immunohistochemical (IHC) assays were performed to evaluate the expression of SOAT1 and immune cell markers, and these results were correlated with clinical parameters and biochemical indices.ResultsSOAT1 expression in gliomas increased with tumor grade. High SOAT1 expression was associated with worse prognosis, and this association remained significant in multivariable Cox models. Immune infiltration analysis revealed a significant positive association between SOAT1 expression and multiple tumor-infiltrating immune cells, particularly monocytes-macrophages and neutrophils. Furthermore, patients with high SOAT1 expression exhibited elevated circulating neutrophils, neutrophil-to-lymphocyte ratio (NLR), (white blood cell-neutrophil)-to-lymphocyte ratio (dNLR) and systemic immune-inflammation index (SII), accompanied by decreased lymphocyte and monocyte counts. Additionally, high SOAT1 expression was associated with reduced serum sodium (Na⁺) and chloride (Cl⁻) levels, as well as increased levels of bilirubin.ConclusionSOAT1 expression is closely associated with glioma prognosis, immune cell infiltration, systemic inflammatory and biochemical indicators. These findings offer novel insights into the role of SOAT1 in glioma and its broader implications for systemic immune and biochemical alterations, providing a foundation for future research into potential therapeutic targets and prognostic biomarkers.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-026-05328-y.Keywords: Sterol O-acyltransferase 1, Glioma, Prognosis, Immune infiltration, Biochemical indicators Introduction Glioma is the most prevalent and aggressive primary malignant tumor of the central nervous system, accounting for approximately 80% of all malignant brain neoplasms and serving as the leading cause of death among patients with primary brain tumors(1,2) [1, 2]. Globally, the annual incidence of gliomas is estimated at 5–8 cases per 100,000 population [1]. Among these, World Health Organization (WHO) grade IV glioblastoma (GBM) remains the most lethal subtype. Despite advancements in surgical resection, radiotherapy, and chemotherapy, the median survival of GBM patients remains under two years, with a 5-year survival rate of less than 10% [3]. Recent studies have highlighted the critical role of the tumor microenvironment (TME) in glioma initiation, progression, and therapeutic resistance [4–6]. TME is largely dependent on metabolic pathways for support, among which lipid metabolism plays a pivotal role. Dysregulated lipid metabolism has been identified as a key driver of glioma progression and can reprogram immune cell functions within the TME [7–9]. Lipid metabolism is a fundamental metabolic pathway responsible for energy production, cell membrane synthesis, and signal transduction in living organisms [7]. Its aberrant reprogramming has been established as a critical feature of tumor progression and a potential therapeutic target [7]. In the context of lipid metabolic reprogramming, cholesterol esterification is a critical step, with sterol O-acyltransferase 1 (SOAT1) acting as a key enzyme in this process [10]. SOAT1 catalyzes the esterification of cholesterol with fatty acids to form cholesterol esters, which are stored in lipid droplets [11]. This process not only maintains intracellular cholesterol homeostasis but also provides energy and structural components to support rapid tumor cell proliferation and biosynthesis [11, 12]. Previous studies have indicated that elevated SOAT1 expression is associated with poor prognosis in liver cancer, pancreatic cancer and prostate cancer [13–16]. However, the expression of SOAT1 in glioma and its prognostic significance have not been fully elucidated. This study aims to investigate the association between SOAT1 expression and patient prognosis, immune environment, and biochemical indicators in glioma. Immunohistochemical (IHC) analysis was performed to examine the expression of SOAT1 in glioma tissues, as well as immune cell markers. Utilizing data from multiple public databases and clinical information from 195 glioma patients, we analyzed the association between SOAT1 expression and glioma pathological grade, as well as prognosis. Additionally, we explored the association between SOAT1 expression and immune cell infiltration within the TME. Furthermore, the study assessed the association between SOAT1 and systemic immune status, lipid levels, coagulation, electrolyte balance, as well as liver and kidney function indicators. The findings of this study offer novel insights and theoretical support for understanding the metabolic regulation of glioma and provide a foundation for the development of potential therapeutic strategies. Materials and methods Data collection of glioma patients We retrospectively collected clinical and pathological data from 254 glioma patients who underwent surgical treatment and were diagnosed with glioma at the Department of Neurosurgery, Fifth Affiliated Hospital of Zhengzhou University, between 2016 and 2020. All patients underwent craniotomy, and postoperative pathological examination confirmed the diagnosis of glioma. Exclusion criteria were as follows: incomplete baseline clinical data or preoperative blood test results, prior chemotherapy or radiotherapy, non-first-time diagnosis of glioma, presence of other malignancies or chronic inflammatory diseases (including autoimmune diseases), and missing or declined follow-up data. 195 glioma patients were included in the analysis (Supplementary Fig. S1, Table 1). This study was approved by the Ethics Committee of the Fifth Affiliated Hospital of Zhengzhou University (KY2021004). Table 1Characteristics of 195 patients with gliomasVariableValueNo. of patients195Gender Male111 (56.9%) Female84 (43.1%)Age < 4897 (49.7%) ≥ 4898 (50.3%)WHO grade High-grade glioma94 (48.2%) Low-grade glioma101 (51.8%)Preoperative KPS ≥ 80154 (79%) < 8041 (21%)Hypertension Yes36 (18.5%) No159 (81.5%)Diabetes Yes15 (7.7%) No180 (92.3%)Epilepsy Yes66 (33.8%) No129 (66.2%) Characteristics of 195 patients with gliomas Data acquisition and analysis In this study, RNA-sequencing data for the CGGA325 cohort were obtained from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn/). TCGA and GTEx RNA-seq data (FPKM) were obtained from UCSC Xena (https://xenabrowser.net/datapages/), where the Toil pipeline was used to uniformly reprocess raw sequencing data [17]. Subsequently, we further applied a log2(FPKM + 1) transformation to meet the assumptions of subsequent statistical analyses. Patients were stratified into high and low SOAT1 expression groups using the median value as the cutoff. The correlation between SOAT1 expression and clinicalpathological characteristics was assessed. Using the TCGA cohort, we performed single-sample gene set enrichment analysis (ssGSEA) with the GSVA R package to assess the association between SOAT1 expression and immune cell infiltration [18], based on immune cell markers reported by Bindea et al. [19]. In addition, we used the “Gene” module of the TIMER tool (https://cistrome.shinyapps.io/timer/) to generate scatterplots illustrating the correlations between SOAT1 expression and macrophage and neutrophil infiltration. Kaplan-Meier survival analysis was conducted to compare overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) between the high and low SOAT1 expression groups. Immunohistochemical staining Paraffin-embedded tissue samples from 195 glioma patients were serially sectioned and mounted on slides pretreated with anti-stripping agents. The sections were incubated overnight at 4 °C with primary antibodies: SOAT1 antibody (Abcam, ab39327, 1:500), CD68 antibody (Servicebio, GB113150, 1:500) and CD11b antibody (Servicebio, GB115693, 1:1000). Following incubation, the sections were incubated with HRP-conjugated secondary antibody (Servicebio, GB23303, 1:200) at room temperature for 50 min. Staining was developed using DAB substrate, and images were captured using a Nikon E100 imaging system. The expression levels of SOAT1, CD68, and CD11b in glioma tissues were scored based on the immune-positive staining area (0‒100%) multiplied by the intensity of staining (0, negative; 1, weak; 2, moderate; and 3, intense). Interobserver agreement was assessed using Cohen’s kappa (κ). The median score was used as the cutoff to define high and low expression. Statistical analysis Statistical analyses were performed using SPSS 23.0, GraphPad Prism 8.0, and R software (version 3.6.3). The Shapiro-Wilk test was used to assess the distribution of variables. For normally distributed data, the Student’s t-test or one-way ANOVA test was used for analysis, with results expressed as mean ± standard deviation (SD). For non-normally distributed data, the Mann-Whitney U test was performed, and results were presented as median and interquartile range (IQR). The proportional hazards (PH) assumption was evaluated using Schoenfeld’s residual test. Where the PH assumption was satisfied, the Cox proportional hazards regression model was applied. Where the assumption was violated, Restricted Mean Survival Time (RMST) analysis was used. P-value < 0.05 was considered statistically significant. Results High SOAT1 expression is associated with malignant progression and poor prognosis in gliomas We analyzed RNA-sequencing data from the TCGA and GTEx databases, revealing that mRNA levels of SOAT1 were significantly elevated in glioma tissues compared to normal brain tissues (P < 0.001) (Fig. 1A). Additionally, SOAT1 expression levels were significantly higher with increasing WHO grade (P < 0.001) (Fig. 1B). Kaplan-Meier analysis showed that patients with high SOAT1 expression had significantly shorter overall survival (OS, HR = 2.44, 95% CI 1.89–3.14, P < 0.001), disease-specific survival (DSS, ΔRMST = 45.4 months, 95% CI 31.1–59.7, P < 0.001), and progression-free interval (PFI, HR = 2.45, 95% CI 2.01–2.99, P < 0.001) compared to those with low SOAT1 expression (Fig. 1C–E). These findings were consistent with RNA‐sequencing data from the CGGA database (Supplementary Fig. S2). We further performed univariate and multivariable Cox regression analysis treating SOAT1 as a continuous variable. The multivariate model, stratified by IDH status, satisfied the proportional hazards assumption. High SOAT1 expression was significantly associated with shorter OS (univariate: HR = 1.031, 95% CI 1.023–1.039, P < 0.001; multivariate: HR = 1.018, 95% CI 1.005–1.030, P = 0.005) (Supplementary Table S2). SOAT1 expression increases with WHO grade and is associated with poor prognosis. A SOAT1 mRNA expression levels in normal brain tissues and glioma tissues (TCGA and GTEx). B Association between SOAT1 expression and WHO grade in glioma (TCGA). C–E Kaplan-Meier curves for OS, DSS, and PFI of glioma patients with high and low SOAT1 expression from the TCGA cohort. F Representative IHC staining of SOAT1 in glioma tissues across different pathological grades (n = 195). Scale bars: 100 μm (100×) and 20 μm (400×). G The prognostic impact of SOAT1 expression on overall survival in our glioma cohort. (H) Predictive performance of SOAT1 for survival by time-dependent ROC analysis. *P < 0.05, **P < 0.01, ***P < 0.001 To validate these results, we assessed SOAT1 expression in tissue samples from 195 glioma patients using IHC. SOAT1 expression levels increased with higher tumor grade (Cohen’s κ = 0.86, Fig. 1F). Follow-up analysis revealed that patients with high SOAT1 expression had significantly shorter overall survival compared to those with low SOAT1 expression (HR = 1.74, 95%CI 1.27–2.37, P < 0.001) (Fig. 1G). We further treated SOAT1 as a continuous variable in Cox regression models. Both univariable and multivariable models consistently demonstrated that higher SOAT1 expression was significantly associated with shorter overall survival (univariable: HR = 1.006, 95% CI 1.003–1.008, P < 0.001; multivariable: HR = 1.004, 95% CI 1.001–1.007, P = 0.011) (Table 2). Similar results were observed in the TCGA cohort, further supporting the prognostic value of SOAT1 in glioma. Table 2Univariate and multivariable Cox regression analyses of OS in 195 patients with gliomaVariableTotal(N)Univariate analysisMultivariate analysisHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-valueGender195Male111ReferenceFemale840.862 (0.631–1.178)0.352WHO grade195Low-grade glioma101ReferenceReferenceHigh-grade glioma944.645 (3.291–6.557)< 0.0014.293 (3.015–6.114)< 0.001Age1951.013 (1.004–1.022)0.0061.011 (1.001–1.020)0.023SOAT11951.006 (1.003–1.008)< 0.0011.004 (1.001–1.007)0.011Epilepsy195No131ReferenceYes641.001 (0.722–1.389)0.995Hypertension195No159ReferenceYes360.825 (0.551–1.233)0.347Diabetes195No180ReferenceYes150.991 (0.550–1.786)0.976Preoperative KPS195≥ 80154ReferenceReference< 80411.417 (0.980–2.048)0.0641.242 (0.857–1.799)0.253 Univariate and multivariable Cox regression analyses of OS in 195 patients with glioma To further evaluate the prognostic performance of SOAT1, we conducted time-dependent ROC curve analyses. SOAT1 exhibited stronger predictive accuracy for 1-year survival (AUC = 0.706) compared with 3-year (AUC = 0.685) and 5-year survival (AUC = 0.645) (Fig. 1H). Using the optimal cutoff (cutoff = 50) derived from the 1-year ROC curve, patients were stratified into high and low expression groups. Kaplan-Meier analysis based on this cutoff revealed a significant survival difference (HR = 1.77, 95% CI 1.28–2.44, P < 0.001, Supplementary Fig. S3). Additionally, we analyzed the TCGA database, revealing a significant association between SOAT1 expression and several clinicopathological characteristics, including age (P < 0.001), WHO grade (P < 0.001), IDH status (P < 0.001) and 1p/19q codeletion (Supplementary Table S3, Supplementary Fig. S4). To further validate these findings, we categorized SOAT1 expression into high and low expression groups based on IHC analysis from our cohort, followed by clinical-pathological characteristic analysis. The results showed that high SOAT1 expression (56.4%) was more frequently observed in high-grade gliomas compared to low expression (39.4%) (P = 0.017) (Table 3). However, no significant associations were found in terms of gender (P = 0.17), age (P = 0.19), epilepsy (P = 0.335), hypertension (P = 0.811), diabetes (P = 0.901), or preoperative Karnofsky Performance Status (KPS, P = 0.309) (Table 3). Taken together, these results suggest that SOAT1 expression increases with glioma grade and is closely associated with poor prognosis. Table 3Differences in clinicopathological characteristics between high and low SOAT1 expression groupsVariableHigh expression of SOAT1Low expression of SOAT1P-valueNo. of patients10194Gender0.17male62 (61.4%)49 (52.1%)Female39 (38.6%)45 (47.9%)Age0.19< 4847 (46.5%)50 (53.2%)≥ 4854 (53.5%)44 (46.8%)WHO grade0.017High-grade glioma57 (56.4%)37 (39.4%)Low-grade glioma44 (43.6%)57 (60.6%)Epilepsy0.335Yes31 (30.7%)35 (37.2%)No70 (69.3%)59 (62.8%)Hypertension0.811Yes18 (17.8%)18 (19.1%)No83 (82.2%)76 (80.9%)Diabetes0.901Yes8 (7.9%)7 (7.4%)No93 (92.1%)87 (92.6%)Preoperative KPS0.309≥ 8076 (75.2%)78 (83.0%)< 8025 (24.8%)16 (17%) Differences in clinicopathological characteristics between high and low SOAT1 expression groups Correlation analysis of SOAT1 expression with tumor microenvironment and peripheral blood immune inflammation markers We employed the ssGSEA algorithm based on the TCGA cohort to assess the relationship between SOAT1 expression and immune cell infiltration in the TME. The results indicated that high SOAT1 expression was significantly positively correlated with the infiltration of several important immune cell types, including macrophages (R = 0.629, P < 0.001), neutrophils (R = 0.546, P < 0.001), activated dendritic cells (aDC, R = 0.582, P < 0.001), Th2 cells (R = 0.515, P < 0.001), eosinophils (R = 0.535, P < 0.001), and T helper cells (R = 0.441, P < 0.001). In contrast, SOAT1 expression showed a significant negative correlation with plasmacytoid dendritic cells (pDC, R = -0.441, P < 0.001) and NK CD56bright cells (R = -0.418, P < 0.001) (Fig. 2A). According to TIMER, the expression level of SOAT1 was positively related with macrophages and neutrophils (Fig. 2B). We explored the correlation between SOAT1 and immune checkpoint-related genes. SOAT1 demonstrated significant correlations with 29 immune regulators (P < 0.05), showing negative associations with CD200, HHLA2 but positive links to CD276, PDCD1, CD86 and CD80 (Fig. 2C). Correlation between SOAT1 and immune infiltration. A Lollipop graph showing positive correlation between high SOAT1 expression and infiltration of multiple immune cell types. B Scatter plots showing the expression level of SOAT1 was positively correlated with the infiltration level of macrophage and neutrophil according to TIMER. C Correlation between SOAT1 and immune checkpoint-related genes. *P < 0.05, **P < 0.01, ***P < 0.001, ns indicates no significant difference (P > 0.05) compared to low SOAT1 expression We further investigated the association between SOAT1 protein expression and monocyte-macrophage and neutrophil infiltration in 195 glioma samples using IHC. Our analysis revealed that gliomas with high SOAT1 expression exhibited significantly higher infiltration of the monocyte-macrophage marker CD68 (60.4% vs. 40.4%, P = 0.006; Cohen’s κ = 0.85) and the neutrophil marker CD11b (52.5% vs. 38.3%, P = 0.048; Cohen’s κ = 0.83) than those with low SOAT1 expression (Fig. 3; Table 4). Tumor-infiltrating immune cells in high and low SOAT1 expression groups based on IHC data from our cohort. A, B Representative IHC staining of CD68⁺ monocyte-macrophages in glioma tissues with low (A) and high (B) SOAT1 expression. C, D Representative IHC staining of CD11b⁺ neutrophils in glioma tissues with low (C) and high (D) SOAT1 expression. Scale bars: 100 μm (100×) and 20 μm (400×) Table 4Differences in monocyte-macrophage and neutrophil infiltration between high and low SOAT1 expression groupsVariableHigh expression of SOAT1Low expression of SOAT1P-valueNo. of patients10194Expression of CD680.006High61 (60.4%)38 (40.4%)Low40 (39.6%)56 (59.6%)Expression of CD11b0.048High53 (52.5%)36 (38.3%)Low48 (47.5%)58 (61.7%) Differences in monocyte-macrophage and neutrophil infiltration between high and low SOAT1 expression groups We compared the immune markers in routine blood tests of 195 glioma patients and found that neutrophil levels (NEUT, 5.1 (3.31, 7.11) vs. 3.82 (3.11, 5.45), P = 0.029) and their proportion (NEUT %, 68.24 ± 14.23 vs. 62.13 ± 11.89, P = 0.001) were significantly higher in gliomas with high SOAT1 expression. In contrast, lymphocytes (LYMPH, 1.65 (1.09, 2.08) vs. 1.80 (1.3, 2.39), P = 0.016) and their proportion (LYMPH %, 23.26 ± 11.75 vs. 27.90 ± 10.45, P = 0.004), monocytes (MONO, 0.44 (0.31, 0.57) vs. 0.49 (0.4, 0.62), P = 0.043) and their proportion (MONO %, 6.6 (4.1, 8.35) vs. 7.05 (5.75, 8.9), P = 0.014) were significantly lower in the high SOAT1 expression group compared to the low SOAT1 expression group. No significant differences were observed between high and low SOAT1 expression groups in white blood cells (WBC, P = 0.154), platelets (PLT, P = 0.257), eosinophils (EOS, P = 0.493), or basophils (BASO, P = 0.616) (Table 5; Fig. 4). Table 5Comparison of hematological variables between high and low SOAT1 expression groupsVariableHigh expressionof SOAT1Low expressionof SOAT1P-valueWBC (10^9/L)7.14 (5.67, 8.98)6.6 (5.4, 8.4)0.154NEUT (10^9/L)5.1 (3.31, 7.11)3.82 (3.11, 5.45)0.029LYMPH (10^9/L)1.65 (1.09, 2.08)1.80 (1.3, 2.39)0.016MONO (10^9/L)0.44 (0.31, 0.57)0.49 (0.4, 0.62)0.043EOS %1.2 (0.7, 2.2)1.6 (0.78, 2.4)0.322BASO %0.4 (0.2, 0.5)0.4 (0.3, 0.5)0.298NEUT %68.24 ± 14.2362.13 ± 11.890.001LYMPH %23.26 ± 11.7527.90 ± 10.450.004MONO%6.6 (4.1, 8.35)7.05 (5.75, 8.9)0.014EOS(10^9/L)0.1 (0.04, 0.16)0.1 (0.06, 0.19)0.493BASO(10^9/L)0.01 (0, 0.03)0.02 (0, 0.03)0.616RBC (10^12/L)4.37 (4.07, 4.67)4.38 (4.06, 4.72)0.942HGB (g/L)132 (123.15, 143)131.5 (122.98, 141.8)0.621HCT0.39 (0.36, 0.43)0.39 (0.36, 0.42)0.686MCV (fL)90.6 (87.3, 93.5)90.85 (87.43, 93.8)0.873MCH (pg)30.7 (29.25, 32)30.55 (29.18, 31.93)0.762MCHC (g/L)338 (328, 345)338 (328, 345)0.858PLT(10^9/L)218 (175, 256)226.5 (185, 276.5)0.257MPV(fL)8.2 (7.5, 9.1)8.35 (7.5, 9.1)0.574RDW (%)16.4 (16.1, 16.9)16.5 (16.18, 16.9)0.785PCT(%)0.18 (0.14, 0.21)0.19 (0.16, 0.22)0.148 Comparison of hematological variables between high and low SOAT1 expression groups Impact of SOAT1 expression on circulating immune cells in glioma patients. A‒J Patients with high SOAT1 expression exhibited elevated neutrophil levels (absolute counts and percentages) and reduced lymphocytes and monocytes (absolute counts and percentages). *P < 0.05, **P < 0.01, ***P < 0.001, ns indicates P > 0.05 when compared to SOAT1 low expression As key indicators of systemic inflammation and immune response, the Neutrophil-to-lymphocyte ratio (NLR) and the (white blood cell-neutrophil)-to-lymphocyte ratio (dNLR) are associated with immune suppression and a tumor-promoting state in cancer patients. We found that patients with high SOAT1 expression exhibited significantly higher NLR (P < 0.01) and dNLR (P < 0.01) levels compared to those with low SOAT1 expression (Fig. 5). The Systemic Immune-Inflammation Index (SII), which is a composite score based on peripheral blood platelet, neutrophil, and lymphocyte counts, has been validated by multiple studies as an important prognostic and immune-inflammation marker for cancer patients [20–22]. In our cohort, the SII was also significantly elevated in patients with high SOAT1 expression (P < 0.05) (Fig. 5). Association between SOAT1 expression and peripheral inflammatory markers in glioma patients. A‒J Patients with high SOAT1 expression exhibited elevated levels of NLR, dNLR and SII based on peripheral blood indices from our cohort. *P < 0.05, **P < 0.01, ***P < 0.001, ns indicates no significant difference (P > 0.05) compared to low SOAT1 expression No significant differences between SOAT1 expression and lipid profiles We further explored the association between SOAT1 expression levels and lipid metabolism markers in patients. The results indicated that, despite the critical role of SOAT1 in lipid metabolism regulation, no significant differences were observed between SOAT1 expression levels and preoperative lipid profiles (TC, TG, HDL-C, LDL-C, Apo-A1, Apo-B, Lp(a)) (Table 6). Table 6Comparison of lipid profiles between high and low SOAT1 expression groupsVariableHigh expression of SOAT1Low expression of SOAT1P-valueTC(mmol/L)4.44 (3.97, 5.09)4.66 (3.96, 5.25)0.539TG(mmol/L)1.27 (0.92, 2.10)1.23 (0.81, 2.15)0.424HDL-C(mmol/L)1.11 (0.95, 1.26)1.13 (0.96, 1.31)0.469LDL-C(mmol/L)2.61 ± 0.912.68 ± 0.840.559Apo-A1(g/L)1.18 (0.99, 1.27)1.2 (1.0, 1.33)0.585Apo-B(g/L)0.88 (0.67, 1.09)0.79 (0.69, 1.0)0.206Lp(a)(mg/L)103.6 (51.1, 202.9)83.8 (41.2, 192.6)0.375 Comparison of lipid profiles between high and low SOAT1 expression groups Association between SOAT1 expression and coagulation, electrolyte balance, and liver and renal function markers We investigated the relationship between SOAT1 expression and coagulation function, electrolyte balance, and liver and renal function markers in patients. The results showed that there were no significant differences in preoperative coagulation markers (PT, INR, PTA, APTT, and FIB) between high and low SOAT1 expression groups. Notably, patients with elevated SOAT1 expression displayed significantly lower sodium (Na⁺, 138.7 (136, 140.5) vs. 139.75 (137.98, 142.05), P = 0.002) and chloride (Cl⁻, 103.1 (99.75, 105.4) vs. 104.8 (100.8, 106.63), P = 0.027) levels (Table 7). Regarding liver function, significantly higher levels of total bilirubin (TBIL, P = 0.003), direct bilirubin (DBIL, P = 0.01), and indirect bilirubin (IBIL, P = 0.009) were observed in patients with high SOAT1 expression (Table 7). No significant differences were observed in renal function markers between high and low SOAT1 expression groups (Table 7). Table 7Comparison of coagulation, electrolyte balance, and liver and renal function between high and low SOAT1 expression groupsVariableHigh expression of SOAT1Low expression of SOAT1P-valuePT(s)10 (9.1, 10.8)9.7 (9, 10.43)0.286INR0.90 ± 0.090.89 ± 0.090.349PTA(%)117 (107, 139.5)124 (108.5, 137.5)0.327APTT(s)30.6 (28.15, 34.1)30.65 (27.58, 34.45)0.638FIB(g/L)3.34 (2.82, 3.84)3.14 (2.71, 3.68)0.079TT(s)13.4 (12.5, 13.9)13.2 (12.5, 13.93)0.850DD(mg/L)0.3 (0.1, 0.8)0.25 (0.1, 0.4)0.342FDP(mg/L)1 (0.5, 1.65)0.7 (0.5, 1.15)0.094K(mmol/L)4.04 (3.77, 4.24)4.05 (3.7, 4.33)0.828Na(mmol/L)138.7 (136, 140.5)139.75 (137.98, 142.05)0.002Cl(mmol/L)103.1 (99.75, 105.4)104.8 (100.8, 106.63)0.027Ca(mmol/L)2.21 (2.12, 2.33)2.22 (2.12, 2.34)0.87CO2(mmol/L )25.45 (23.83, 27.3)26.3 (24.48, 28.23)0.081TBIL(µmol/L)10.8 (8, 14.95)9.1 (6.93, 11.35)0.003DBIL(µmol/L)2.6 (1.9, 3.2)2.15 (1.58, 2.7)0.01TP(g/L)63.6 (60.05, 69.9)63.5 (60.28, 69.3)0.61ALB(g/L)38.39 ± 5.4438.69 ± 5.090.694ALT(U/L)21 (14, 35.5)22.5 (13.75, 31)0.58AST(U/L)20 (16.25, 26)19 (16, 24)0.246ALP(U/L)87 (70, 107)81.5 (67, 101.25)0.241GGT(U/L)26 (13, 43.5)28.5 (17, 53.5)0.217GLO(g/L)26.61 ± 4.0925.71 ± 4.520.146IBIL(µmol/L)8.3 (6, 11.2)6.9 (5.53, 9)0.009ALB/GLO1.46 (1.27, 1.64)1.52 (1.32, 1.70)0.158BUN(mmol/L)5 (3.75, 6.1)4.6 (3.8, 5.83)0.308CREA(µmol/L)58 (49, 67)59.5 (50, 72.25)0.467UA(µmol/L)231 (153, 291)240 (166, 324.25)0.078CYSC(mg/L)0.87 (0.72, 1.11)0.93 (0.68, 1.13)0.476β2-MG(mg/L )1.45 (1.15, 1.99)1.62 (1.30, 2.0)0.085 Comparison of coagulation, electrolyte balance, and liver and renal function between high and low SOAT1 expression groups Discussion Abnormalities in lipid metabolism have been strongly associated with the WHO grade, clinical prognosis, and drug resistance in glioma [23, 24]. Investigating the changes in lipid metabolism in glioma is crucial for understanding their pathogenesis, microenvironmental characteristics, and for identifying potential biomarkers and therapeutic targets. This study utilized bioinformatics analysis, retrospective clinical data analysis, and immunohistochemistry techniques to analyze the associations between SOAT1 expression and the prognosis, as well as its correlation with the immune environment and biochemical indicators in patients with glioma. SOAT1 facilitates the conversion of excess free cholesterol into cholesteryl esters and their sequestration within lipid droplets, thereby maintaining intracellular cholesterol homeostasis [25, 26]. This process has been shown to support tumor cell proliferation and survival [27–30]. In glioma, SOAT1 is associated with malignancy grade [23, 31]. Our study found that SOAT1 expression levels in gliomas increased progressively with WHO grade, consistent with the findings of Geng et al. [23]. Additionally, patients with high SOAT1 expression exhibited significantly shorter overall survival, and this association remained significant after multivariable adjustment for clinicopathologic covariates across TCGA and our cohort. These findings support SOAT1 as an independent prognostic biomarker and a potential contributor to glioma progression. Lipid metabolic reprogramming plays a critical role in regulating immune cell function and inflammatory signaling within the tumor microenvironment [32]. Recent studies have identified SOAT1 as a pivotal metabolic-immune regulator [33]. Consistent with these findings, our analysis revealed that high SOAT1 expression was strongly associated with immune cell infiltration in the TME, particularly with a notable increase in macrophage and neutrophil infiltration. In glioma, increased infiltration of macrophages and neutrophils within the tumor immune microenvironment is closely associated with immunosuppression, tumor progression, and poor prognosis [34, 35]. Therefore, the high-SOAT1 expression group may be characterized by an immunosuppressive microenvironment. Evidence indicates that inhibition of SOAT1 disrupts lipid homeostasis and activates the NF-κB signaling pathway, leading to increased chemokine expression and enhanced antitumor immunity [33]. In addition, SOAT1 regulates cytokine secretion by tumor cells as well as CD8⁺ T cell–mediated immune responses [36]. Studies have identified SOAT1 as a metabolic immune checkpoint, whose inhibition promotes antitumor immunity through the release of 20(S)-hydroxycholesterol (20SOHC) and subsequent activation of the GPR132 signaling pathway [37]. Notably, SOAT1 has also been reported to facilitate the polarization of tumor-associated macrophages toward the M2 phenotype via activation of the SREBP1-mediated PI3K/AKT/mTOR pathway, thereby contributing to the establishment of an immunosuppressive tumor microenvironment [38]. Collectively, these findings suggest that SOAT1 may participate in shaping an immunosuppressive tumor immune microenvironment in glioma through multiple mechanisms. In tumor patients, an increase in peripheral blood neutrophils is frequently indicative of a chronic inflammatory response. By releasing reactive oxygen species (ROS), reactive nitrogen species (RNS), and angiogenic factors such as MMP-9, neutrophils promote a tumor-supportive microenvironment that facilitates tumor initiation and progression [39]. Furthermore, elevated neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII), as composite markers of systemic inflammation, are strongly associated with advanced tumor grade, enhanced invasiveness, and poor prognosis [40, 41]. In this study, we observed that glioma patients with high SOAT1 expression exhibited a significant increase in circulating neutrophils, along with elevated NLR, dNLR, and SII, accompanied by a reduction in lymphocytes and monocytes. These results suggest that SOAT1 may play a pivotal role in modulating the systemic immune and metabolic processes in glioma. We found that, although SOAT1 is a key enzyme in cholesterol esterification, its expression was not significantly correlated with circulating lipid profiles (TC, TG, HDL-C, LDL-C, Apo-A1, Apo-B, Lp(a)). Due to the blood–brain barrier (BBB), brain cholesterol metabolism is largely independent of peripheral tissues [42, 43]. SOAT1, located in the endoplasmic reticulum, regulates cholesterol storage and fatty acid metabolism primarily within local cells [10], with elevated SOAT1 expression notably observed in tumor cells such as those from hepatocellular carcinoma and pancreatic cancer [13, 14]. In plasma, cholesterol esters are mainly synthesized by lecithin cholesterol acyltransferase (LCAT) [44]. In a matched analysis of GBM tissue and patient plasma, Gilard et al. detected only 10 overlapping lipid species with poor correlations between tissue and plasma levels [45]. Moreover, variability in metabolic was also markedly higher in tumor tissues (CV ~ 127%) than in plasma (CV ~ 36%) [45]. Patients with elevated SOAT1 expression demonstrated a marked decrease in serum sodium (Na⁺) and chloride (Cl⁻) levels, indicative of electrolyte imbalance. Hyponatremia is a frequently encountered complication in malignancies, most commonly attributable to the syndrome of inappropriate antidiuresis (SIAD) [43]. Research has demonstrated that ectopic lipid accumulation may impair renal cell function [46]. However, the specific mechanisms by which SOAT1 affects electrolyte balance remain unclear. In addition, patients with high SOAT1 expression exhibited elevated circulating bilirubin levels, a clinical marker often associated with hemolytic anemia or hepatic dysfunction. These findings highlight the importance of monitoring electrolyte and liver function in glioma patients with high SOAT1 expression, which may facilitate timely intervention and mitigate complications arising from metabolic derangements. This study suggests that SOAT1 may play a key role in regulating the TME in glioma and influencing systemic metabolic and physiological states. Previous studies have reported that the SOAT1 inhibitor avasimibe reduces cholesterol ester levels, inhibits the activity of SREBPs, and ultimately suppresses cancer cell proliferation in prostate cancer and glioblastoma [23, 30]. In hepatocellular carcinoma, the SOAT1-targeting compound nilotinib reprograms cholesterol metabolism in tumor cells and enhances CD8 + T cell and neutrophil activity, significantly inhibiting tumor growth both in vitro and in vivo [47]. However, its application in glioma therapy still faces challenges. Firstly, the central nervous system (CNS) penetration profile of avasimibe remains incompletely characterized in humans. Secondly, nilotinib has been shown to cross the blood–brain barrier (BBB) and achieve measurable concentrations in the cerebrospinal fluid (CSF) of Parkinson’s patients [48]. However, its CNS exposure remains relatively low, with a CSF-to-plasma ratio of approximately 0.5–1% [48]. Furthermore, SOAT1 is widely expressed across multiple tissues, particularly in the liver and adrenal glands, where its expression levels are relatively high. Therefore, caution should be exercised when using SOAT1 inhibitors due to the potential side effects, especially in these high-expression organs. To address these issues, nanotechnology or carrier-mediated targeted delivery systems could be employed to enhance drug delivery efficiency while improving targeting specificity for glioma. This study has several limitations that should be acknowledged. Firstly, it is a single-center retrospective analysis, which inherently introduces a risk of selection bias and time bias. The retrospective design also led to incomplete data on some clinically relevant variables, such as corticosteroid use, concomitant infections, comorbidities and related medications, radiographic assessments, IDH mutation status, and 1p/19q codeletion, which may affect systemic inflammation and survival outcomes. Moreover, although we made every effort to include relevant patient data, the single-institution nature of this study may limit the generalizability of our findings to the broader glioma population. Future prospective, multi-center studies with standardized collection of clinical, therapeutic, and molecular data are warranted to validate our results and further elucidate the role of SOAT1 in glioma progression and prognosis. Conclusion Elevated SOAT1 expression was significantly associated with higher WHO grade and shorter survival. Additionally, increased SOAT1 levels correlated with enhanced infiltration of macrophages and neutrophils in the TME, as well as elevated systemic inflammatory markers (NLR, dNLR, SII). Notably, beyond the TME, higher SOAT1 expression was also associated with lower serum sodium (Na⁺) and chloride (Cl⁻) and higher bilirubin. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary File 1 Supplementary File 2 Supplementary File 3 Supplementary File 4 Supplementary_Tables Acknowledgements Not applicable Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Author contributions X.W. conceptualized the study. X.W., W.H. and W.L. developed the study protocol. X.G., F.W., Q.W., C.Z., S.L. and Z.J. analyzed the data. W.H., W.L., H.L., B.L. and A.H. was responsible for statistical analyses and interpretations of the data. W.H. and W.L. drafted the manuscript, which was critically revised by other authors. S.Z. and X.F. were involved in supervision. X.W. accessed and validated the data. All authors reviewed and approved the final version of the manuscript. Funding This study was supported by the fund from the Zhengzhou Science and Technology Innovation Project for Healthcare (2024YLZDJH027), National Natural Science Foundation of China (82473349, 82303029), Science and Technology of Henan Province (231111521000, 232102311134), Henan Province Science and Technology Key Project (252102311049), Health Commission of Henan province (YXKC2022020). Data availability The data supporting this study are available from the corresponding author upon reasonable request, subject to institutional ethics approval and a data use agreement. Declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Fifth Affiliated Hospital of Zhengzhou University (KY2021004). All participants provided written informed consent to participate in this study. Consent for publication Not applicable. No identifying images or personal data are included in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Weihua Hu and Wulong Liang have contributed equally to this work. References Associated Data Data Citations Supplementary Materials Supplementary File 1 Supplementary File 2 Supplementary File 3 Supplementary File 4 Supplementary_Tables Data Availability Statement The data supporting this study are available from the corresponding author upon reasonable request, subject to institutional ethics approval and a data use agreement.